US-based biotechnology company Foghorn Therapeutics has dosed the first patient in a Phase I study of FHD-286 along with decitabine or cytarabine to treat relapsed and/or refractory acute myelogenous leukaemia (AML).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,